Vollständiger Abstract
Worum geht es in dieser Arbeit?
AbstractIMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tumors expressing ≥1 of 8 predefined targets underwent leukapheresis. Endogenous T cells specific for up to 4 targets were primed and expanded in vitro. Patients received lymphodepletion (fludarabine, cyclophosphamide), followed by T-cell infusion and low-dose IL2 (Cohort 1). Patients in Cohort 2 received atezolizumab for up to 1 year (NCT02876510). Overall, 214 patients were screened, 15 received lymphodepletion (13 women, 2 men; median age, 44 years), and 14 were treated with T-cell products. IMA101 treatment was feasible and well tolerated. The most common adverse events were cytokine release syndrome (Grade 1, n = 6; Grade 2, n = 4) and expected cytopenias. No patient died during the first 100 days after T-cell therapy. No neurotoxicity was observed. No objective responses were noted. Prolonged disease stabilization was noted in three patients lasting for 13.7, 12.9, and 7.3 months. High frequencies of target-specific T cells (up to 78.7% of CD8+ cells) were detected in the blood of treated patients, persisted for >1 year, and were detectable in posttreatment tumor tissue. Individual T-cell receptors (TCR) contained in T-cell products exhibited broad variation in TCR avidity, with the majority being low avidity. High-avidity TCRs were identified in some patients’ products. This study demonstrates the feasibility and tolerability of an actively personalized ACT directed to multiple defined pHLA cancer targets. Results warrant further evaluation of multi-target ACT approaches using potent high-avidity TCRs.See related Spotlight by Uslu and June, p. 865
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Apostolia M. Tsimberidou, Kerstin Guenther, Borje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van Karlyle Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras-Gonzalez, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer
- Quelle
- American Association for Cancer Research (AACR)
- Publikation
- 2023-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- Nicht angegeben
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Apostolia M. Tsimberidou, Kerstin Guenther, Borje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van Karlyle Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras-Gonzalez, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer (2023). Data from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. https://doi.org/10.1158/2326-6066.cir-26-0160
Kontext
Themen, Förderung und Nutzung
Lizenzhinweise: Lizenz 1